443
Registered trials
168
Recruiting
240
Completed trials
191
Sponsors
25
Countries
Phase III:
154
Phase II/III:
20
Phase II:
171
Phase I/II:
45
Phase III/IV:
3
Phase IV:
12
Phase I:
3
Phase I (Other):
3
Phase I (FiH):
31
Other:
1
Oversight events:
12 serious breaches
59 temporary halts
7 urgent safety measures
13 unexpected events
13 corrective measures
across 46 trials
View oversight register →
Indications tested
Non-small cell lung cancer
40
Non-small cell lung cancer metastatic
29
Triple negative breast cancer
14
Squamous cell carcinoma of head and neck
12
Non-small cell lung cancer stage IV
11
Non-small cell lung cancer stage IIIB
10
Malignant melanoma
7
Colorectal cancer metastatic
6
Ovarian cancer
5
Metastatic renal cell carcinoma
5
Non-small cell lung cancer stage IIIA
5
Malignant melanoma stage III
5
Sponsors using this IMP
Merck Sharp & Dohme LLC
115
AstraZeneca AB
13
Unicancer
10
Genmab A/S
9
Bristol-Myers Squibb Services Unlimited Company
6
Pfizer Inc.
6
Daiichi Sankyo Inc.
5
Fondazione IRCCS Istituto Nazionale Dei Tumori
5
Gilead Sciences Inc.
5
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
5
Institut Gustave Roussy
5
Seagen Inc.
5
All trials — page 2
443 total-
RESET C2 Pending
Showing 25–48 of 443 trials